Risk of venous thromboembolism during treatment with antipsychotic agents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10126128" target="_blank" >RIV/00179906:_____/12:10126128 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10126128

Výsledek na webu

<a href="http://dx.doi.org/10.1111/pcn.12001" target="_blank" >http://dx.doi.org/10.1111/pcn.12001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/pcn.12001" target="_blank" >10.1111/pcn.12001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk of venous thromboembolism during treatment with antipsychotic agents

Popis výsledku v původním jazyce

The evidence to date on the relation between the risk of venous thromboembolic disease (VTE) and antipsychotic agents derives primarily from observational and case history studies. While an increased risk of VTE has been associated with first-generationlow-potency antipsychotic agents, particularly clozapine, there appears to be a growing number of reports on the occurrence of this adverse reaction during the use of second-generation antipsychotics, such as risperidone and olanzapine. The highest riskof pathological blood clotting emerges during the first 3 months after initiation of treatment with the product. Potential etiopathogenetic factors leading to VTE during treatment with antipsychotic agents include sedation, obesity, elevation of antiphospholipid antibodies, increased platelet activation and aggregation, hyperhomocysteinemia, and hyperprolactinemia. Diagnoses of schizophrenia and/or bipolar affective disorder, as well as hospitalization or stress with sympathetic activati

Název v anglickém jazyce

Risk of venous thromboembolism during treatment with antipsychotic agents

Popis výsledku anglicky

The evidence to date on the relation between the risk of venous thromboembolic disease (VTE) and antipsychotic agents derives primarily from observational and case history studies. While an increased risk of VTE has been associated with first-generationlow-potency antipsychotic agents, particularly clozapine, there appears to be a growing number of reports on the occurrence of this adverse reaction during the use of second-generation antipsychotics, such as risperidone and olanzapine. The highest riskof pathological blood clotting emerges during the first 3 months after initiation of treatment with the product. Potential etiopathogenetic factors leading to VTE during treatment with antipsychotic agents include sedation, obesity, elevation of antiphospholipid antibodies, increased platelet activation and aggregation, hyperhomocysteinemia, and hyperprolactinemia. Diagnoses of schizophrenia and/or bipolar affective disorder, as well as hospitalization or stress with sympathetic activati

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Psychiatry and Clinical Neurosciences

ISSN

1323-1316

e-ISSN

—

Svazek periodika

66

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

541-552

Kód UT WoS článku

000312649000001

EID výsledku v databázi Scopus

—